Geoffrey R. Oxnard
0000-0003-1054-8240
Publication & Citation Trends
Most Cited Works
Publications
995 total
Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapy.
Cited by 0
Semantic Scholar
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples OA
Cited by 2
Semantic Scholar
Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Cited by 11
Semantic Scholar
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study
Cited by 1
Semantic Scholar
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials.
Cited by 1
Semantic Scholar
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Cited by 12
Semantic Scholar
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
Cited by 27
Semantic Scholar
Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation OA
Cited by 70
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(595)
Cancer Genomics and Diagnostics
(420)
Lung Cancer Research Studies
(196)
Lung Cancer Diagnosis and Treatment
(145)
RNA modifications and cancer
(99)
Frequent Co-Authors
Affiliations
Boston University
Brigham and Women's Hospital
Boston Medical Center
Beth Israel Deaconess Medical Center
Hudson Institute